NEW YORK (GenomeWeb) – Genomic analysis startup Genoox announced today that it has raised $6 million in a new funding round.
Genoox's next-generation sequencing technology employs machine learning algorithms to analyze large amounts of genetic data. The Tel Aviv, Israel-based company entered the US market in 2017 and raised $6 million in a Series A round last June.
The current financing round was led by Triventures, and also included Inimiti Capital and Glilot Capital Partners.
"As a doctor, having access to personalized medicine will transform how we provide care and empower us to deliver the right treatment at the right time," Triventures Cofounder and Managing Partner Peter Fitzgerald said in a statement. "The platform makes it simple and cost-effective to identify the genetic root causes of disease and medical issues, and has even identified new genetic variants that have enabled parents to save their children's lives." Fitzgerald has also joined Genoox's board.
In April, Genoox partnered with Bionano Genomics to develop a genome informatics workflow, which integrates Bionano's structural variant calls with sequencing data within the Genoox platform.